Natixis Acquires New Position in DaVita Inc. (NYSE:DVA)

Natixis acquired a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 11,376 shares of the company's stock, valued at approximately $1,701,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVA. Wellington Management Group LLP increased its position in shares of DaVita by 9.1% in the fourth quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock valued at $405,000 after acquiring an additional 227 shares during the last quarter. Franklin Resources Inc. grew its stake in DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock valued at $8,885,000 after purchasing an additional 31,502 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of DaVita by 201.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock worth $11,159,000 after purchasing an additional 49,885 shares during the last quarter. Hussman Strategic Advisors Inc. raised its stake in shares of DaVita by 200.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $3,769,000 after purchasing an additional 16,800 shares in the last quarter. Finally, Nordea Investment Management AB boosted its holdings in shares of DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock valued at $39,712,000 after buying an additional 12,339 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

DVA traded up $0.01 on Friday, reaching $139.57. The company had a trading volume of 600,714 shares, compared to its average volume of 840,266. The company's fifty day moving average is $146.50 and its 200 day moving average is $155.30. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a market cap of $11.17 billion, a P/E ratio of 13.00, a P/E/G ratio of 1.07 and a beta of 1.04. DaVita Inc. has a fifty-two week low of $130.96 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Finally, Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, DaVita currently has an average rating of "Hold" and a consensus price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.